Global Kidney Cancer Drugs Market Research Report 2022

Global Kidney Cancer Drugs Market Research Report 2022

Table of Contents
1 Kidney Cancer Drugs Market Overview
1.1 Product Overview and Scope of Kidney Cancer Drugs
1.2 Kidney Cancer Drugs Segment by Type
1.2.1 Global Kidney Cancer Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Angiogenesis Inhibitors
1.2.3 mTOR Inhibitors
1.2.4 Monoclonal Antibodies
1.2.5 Cytokine Immunotherapy (IL-2)
1.3 Kidney Cancer Drugs Segment by Application
1.3.1 Global Kidney Cancer Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Renal Cell Carcinoma (RCC)
1.3.3 Transitional Cell Carcinoma (TCC)
1.4 Global Kidney Cancer Drugs Market Size Estimates and Forecasts
1.4.1 Global Kidney Cancer Drugs Revenue 2017-2028
1.4.2 Global Kidney Cancer Drugs Sales 2017-2028
1.4.3 Kidney Cancer Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Kidney Cancer Drugs Market Competition by Manufacturers
2.1 Global Kidney Cancer Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Kidney Cancer Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Kidney Cancer Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Kidney Cancer Drugs Manufacturing Sites, Area Served, Product Type
2.5 Kidney Cancer Drugs Market Competitive Situation and Trends
2.5.1 Kidney Cancer Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Kidney Cancer Drugs Players Market Share by Revenue
2.5.3 Global Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Kidney Cancer Drugs Retrospective Market Scenario by Region
3.1 Global Kidney Cancer Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Kidney Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Kidney Cancer Drugs Market Facts & Figures by Country
3.3.1 North America Kidney Cancer Drugs Sales by Country
3.3.2 North America Kidney Cancer Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Kidney Cancer Drugs Market Facts & Figures by Country
3.4.1 Europe Kidney Cancer Drugs Sales by Country
3.4.2 Europe Kidney Cancer Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Kidney Cancer Drugs Sales by Region
3.5.2 Asia Pacific Kidney Cancer Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Kidney Cancer Drugs Market Facts & Figures by Country
3.6.1 Latin America Kidney Cancer Drugs Sales by Country
3.6.2 Latin America Kidney Cancer Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Kidney Cancer Drugs Sales by Country
3.7.2 Middle East and Africa Kidney Cancer Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Kidney Cancer Drugs Historic Market Analysis by Type
4.1 Global Kidney Cancer Drugs Sales Market Share by Type (2017-2022)
4.2 Global Kidney Cancer Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Kidney Cancer Drugs Price by Type (2017-2022)
5 Global Kidney Cancer Drugs Historic Market Analysis by Application
5.1 Global Kidney Cancer Drugs Sales Market Share by Application (2017-2022)
5.2 Global Kidney Cancer Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Kidney Cancer Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Bayer Kidney Cancer Drugs Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Roche Kidney Cancer Drugs Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 GlaxoSmithKline Kidney Cancer Drugs Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Novartis Kidney Cancer Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Pfizer Kidney Cancer Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott Laboratories
6.6.1 Abbott Laboratories Corporation Information
6.6.2 Abbott Laboratories Description and Business Overview
6.6.3 Abbott Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Abbott Laboratories Kidney Cancer Drugs Product Portfolio
6.6.5 Abbott Laboratories Recent Developments/Updates
6.7 Active Biotech
6.6.1 Active Biotech Corporation Information
6.6.2 Active Biotech Description and Business Overview
6.6.3 Active Biotech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Active Biotech Kidney Cancer Drugs Product Portfolio
6.7.5 Active Biotech Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Amgen Kidney Cancer Drugs Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 Argos Therapeutics
6.9.1 Argos Therapeutics Corporation Information
6.9.2 Argos Therapeutics Description and Business Overview
6.9.3 Argos Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Argos Therapeutics Kidney Cancer Drugs Product Portfolio
6.9.5 Argos Therapeutics Recent Developments/Updates
6.10 ArQule
6.10.1 ArQule Corporation Information
6.10.2 ArQule Description and Business Overview
6.10.3 ArQule Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 ArQule Kidney Cancer Drugs Product Portfolio
6.10.5 ArQule Recent Developments/Updates
6.11 AVEO Pharmaceuticals
6.11.1 AVEO Pharmaceuticals Corporation Information
6.11.2 AVEO Pharmaceuticals Kidney Cancer Drugs Description and Business Overview
6.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.11.4 AVEO Pharmaceuticals Kidney Cancer Drugs Product Portfolio
6.11.5 AVEO Pharmaceuticals Recent Developments/Updates
6.12 Bionomics
6.12.1 Bionomics Corporation Information
6.12.2 Bionomics Kidney Cancer Drugs Description and Business Overview
6.12.3 Bionomics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Bionomics Kidney Cancer Drugs Product Portfolio
6.12.5 Bionomics Recent Developments/Updates
6.13 Bristol-Myers Squibb
6.13.1 Bristol-Myers Squibb Corporation Information
6.13.2 Bristol-Myers Squibb Kidney Cancer Drugs Description and Business Overview
6.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Bristol-Myers Squibb Kidney Cancer Drugs Product Portfolio
6.13.5 Bristol-Myers Squibb Recent Developments/Updates
6.14 Cerulean Pharma
6.14.1 Cerulean Pharma Corporation Information
6.14.2 Cerulean Pharma Kidney Cancer Drugs Description and Business Overview
6.14.3 Cerulean Pharma Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Cerulean Pharma Kidney Cancer Drugs Product Portfolio
6.14.5 Cerulean Pharma Recent Developments/Updates
6.15 Exelixis
6.15.1 Exelixis Corporation Information
6.15.2 Exelixis Kidney Cancer Drugs Description and Business Overview
6.15.3 Exelixis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Exelixis Kidney Cancer Drugs Product Portfolio
6.15.5 Exelixis Recent Developments/Updates
6.16 Genentech
6.16.1 Genentech Corporation Information
6.16.2 Genentech Kidney Cancer Drugs Description and Business Overview
6.16.3 Genentech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Genentech Kidney Cancer Drugs Product Portfolio
6.16.5 Genentech Recent Developments/Updates
6.17 immatics biotechnologies
6.17.1 immatics biotechnologies Corporation Information
6.17.2 immatics biotechnologies Kidney Cancer Drugs Description and Business Overview
6.17.3 immatics biotechnologies Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.17.4 immatics biotechnologies Kidney Cancer Drugs Product Portfolio
6.17.5 immatics biotechnologies Recent Developments/Updates
6.18 Immunicum
6.18.1 Immunicum Corporation Information
6.18.2 Immunicum Kidney Cancer Drugs Description and Business Overview
6.18.3 Immunicum Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Immunicum Kidney Cancer Drugs Product Portfolio
6.18.5 Immunicum Recent Developments/Updates
6.19 Ono Pharmaceutical
6.19.1 Ono Pharmaceutical Corporation Information
6.19.2 Ono Pharmaceutical Kidney Cancer Drugs Description and Business Overview
6.19.3 Ono Pharmaceutical Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Ono Pharmaceutical Kidney Cancer Drugs Product Portfolio
6.19.5 Ono Pharmaceutical Recent Developments/Updates
6.20 Onyx Therapeutics
6.20.1 Onyx Therapeutics Corporation Information
6.20.2 Onyx Therapeutics Kidney Cancer Drugs Description and Business Overview
6.20.3 Onyx Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Onyx Therapeutics Kidney Cancer Drugs Product Portfolio
6.20.5 Onyx Therapeutics Recent Developments/Updates
6.21 Oxford BioMedica
6.21.1 Oxford BioMedica Corporation Information
6.21.2 Oxford BioMedica Kidney Cancer Drugs Description and Business Overview
6.21.3 Oxford BioMedica Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Oxford BioMedica Kidney Cancer Drugs Product Portfolio
6.21.5 Oxford BioMedica Recent Developments/Updates
6.22 Prometheus Laboratories
6.22.1 Prometheus Laboratories Corporation Information
6.22.2 Prometheus Laboratories Kidney Cancer Drugs Description and Business Overview
6.22.3 Prometheus Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.22.4 Prometheus Laboratories Kidney Cancer Drugs Product Portfolio
6.22.5 Prometheus Laboratories Recent Developments/Updates
6.23 Seattle Genetics
6.23.1 Seattle Genetics Corporation Information
6.23.2 Seattle Genetics Kidney Cancer Drugs Description and Business Overview
6.23.3 Seattle Genetics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.23.4 Seattle Genetics Kidney Cancer Drugs Product Portfolio
6.23.5 Seattle Genetics Recent Developments/Updates
6.24 Taiwan Liposome
6.24.1 Taiwan Liposome Corporation Information
6.24.2 Taiwan Liposome Kidney Cancer Drugs Description and Business Overview
6.24.3 Taiwan Liposome Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.24.4 Taiwan Liposome Kidney Cancer Drugs Product Portfolio
6.24.5 Taiwan Liposome Recent Developments/Updates
6.25 Tracon Pharmaceuticals
6.25.1 Tracon Pharmaceuticals Corporation Information
6.25.2 Tracon Pharmaceuticals Kidney Cancer Drugs Description and Business Overview
6.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.25.4 Tracon Pharmaceuticals Kidney Cancer Drugs Product Portfolio
6.25.5 Tracon Pharmaceuticals Recent Developments/Updates
6.26 Wilex
6.26.1 Wilex Corporation Information
6.26.2 Wilex Kidney Cancer Drugs Description and Business Overview
6.26.3 Wilex Kidney Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
6.26.4 Wilex Kidney Cancer Drugs Product Portfolio
6.26.5 Wilex Recent Developments/Updates
7 Kidney Cancer Drugs Manufacturing Cost Analysis
7.1 Kidney Cancer Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Kidney Cancer Drugs
7.4 Kidney Cancer Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Kidney Cancer Drugs Distributors List
8.3 Kidney Cancer Drugs Customers
9 Kidney Cancer Drugs Market Dynamics
9.1 Kidney Cancer Drugs Industry Trends
9.2 Kidney Cancer Drugs Market Drivers
9.3 Kidney Cancer Drugs Market Challenges
9.4 Kidney Cancer Drugs Market Restraints
10 Global Market Forecast
10.1 Kidney Cancer Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Kidney Cancer Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Kidney Cancer Drugs by Type (2023-2028)
10.2 Kidney Cancer Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Kidney Cancer Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Kidney Cancer Drugs by Application (2023-2028)
10.3 Kidney Cancer Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Kidney Cancer Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Kidney Cancer Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Kidney Cancer Drugs Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Kidney Cancer Drugs Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Kidney Cancer Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Kidney Cancer Drugs Market Competitive Situation by Manufacturers in 2021
Table 5. Global Kidney Cancer Drugs Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Kidney Cancer Drugs Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Kidney Cancer Drugs Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Kidney Cancer Drugs Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Kidney Cancer Drugs Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Kidney Cancer Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Kidney Cancer Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Kidney Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Drugs as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Kidney Cancer Drugs Sales by Region (2017-2022) & (K Units)
Table 16. Global Kidney Cancer Drugs Sales Market Share by Region (2017-2022)
Table 17. Global Kidney Cancer Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Kidney Cancer Drugs Revenue Market Share by Region (2017-2022)
Table 19. North America Kidney Cancer Drugs Sales by Country (2017-2022) & (K Units)
Table 20. North America Kidney Cancer Drugs Sales Market Share by Country (2017-2022)
Table 21. North America Kidney Cancer Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Kidney Cancer Drugs Revenue Market Share by Country (2017-2022)
Table 23. Europe Kidney Cancer Drugs Sales by Country (2017-2022) & (K Units)
Table 24. Europe Kidney Cancer Drugs Sales Market Share by Country (2017-2022)
Table 25. Europe Kidney Cancer Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Kidney Cancer Drugs Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Kidney Cancer Drugs Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Kidney Cancer Drugs Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Kidney Cancer Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Kidney Cancer Drugs Revenue Market Share by Region (2017-2022)
Table 31. Latin America Kidney Cancer Drugs Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Kidney Cancer Drugs Sales Market Share by Country (2017-2022)
Table 33. Latin America Kidney Cancer Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Kidney Cancer Drugs Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Kidney Cancer Drugs Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Kidney Cancer Drugs Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Kidney Cancer Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Kidney Cancer Drugs Revenue Market Share by Country (2017-2022)
Table 39. Global Kidney Cancer Drugs Sales by Type (2017-2022) & (K Units)
Table 40. Global Kidney Cancer Drugs Sales Market Share by Type (2017-2022)
Table 41. Global Kidney Cancer Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Kidney Cancer Drugs Revenue Share by Type (2017-2022)
Table 43. Global Kidney Cancer Drugs Price by Type (2017-2022) & (USD/Unit)
Table 44. Global Kidney Cancer Drugs Sales (K Units) by Application (2017-2022)
Table 45. Global Kidney Cancer Drugs Sales Market Share by Application (2017-2022)
Table 46. Global Kidney Cancer Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Kidney Cancer Drugs Revenue Share by Application (2017-2022)
Table 48. Global Kidney Cancer Drugs Price by Application (2017-2022) & (USD/Unit)
Table 49. Bayer Corporation Information
Table 50. Bayer Description and Business Overview
Table 51. Bayer Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. Bayer Kidney Cancer Drugs Product
Table 53. Bayer Recent Developments/Updates
Table 54. Roche Corporation Information
Table 55. Roche Description and Business Overview
Table 56. Roche Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. Roche Kidney Cancer Drugs Product
Table 58. Roche Recent Developments/Updates
Table 59. GlaxoSmithKline Corporation Information
Table 60. GlaxoSmithKline Description and Business Overview
Table 61. GlaxoSmithKline Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. GlaxoSmithKline Kidney Cancer Drugs Product
Table 63. GlaxoSmithKline Recent Developments/Updates
Table 64. Novartis Corporation Information
Table 65. Novartis Description and Business Overview
Table 66. Novartis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Novartis Kidney Cancer Drugs Product
Table 68. Novartis Recent Developments/Updates
Table 69. Pfizer Corporation Information
Table 70. Pfizer Description and Business Overview
Table 71. Pfizer Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. Pfizer Kidney Cancer Drugs Product
Table 73. Pfizer Recent Developments/Updates
Table 74. Abbott Laboratories Corporation Information
Table 75. Abbott Laboratories Description and Business Overview
Table 76. Abbott Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. Abbott Laboratories Kidney Cancer Drugs Product
Table 78. Abbott Laboratories Recent Developments/Updates
Table 79. Active Biotech Corporation Information
Table 80. Active Biotech Description and Business Overview
Table 81. Active Biotech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Active Biotech Kidney Cancer Drugs Product
Table 83. Active Biotech Recent Developments/Updates
Table 84. Amgen Corporation Information
Table 85. Amgen Description and Business Overview
Table 86. Amgen Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Amgen Kidney Cancer Drugs Product
Table 88. Amgen Recent Developments/Updates
Table 89. Argos Therapeutics Corporation Information
Table 90. Argos Therapeutics Description and Business Overview
Table 91. Argos Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Argos Therapeutics Kidney Cancer Drugs Product
Table 93. Argos Therapeutics Recent Developments/Updates
Table 94. ArQule Corporation Information
Table 95. ArQule Description and Business Overview
Table 96. ArQule Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. ArQule Kidney Cancer Drugs Product
Table 98. ArQule Recent Developments/Updates
Table 99. AVEO Pharmaceuticals Corporation Information
Table 100. AVEO Pharmaceuticals Description and Business Overview
Table 101. AVEO Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 102. AVEO Pharmaceuticals Kidney Cancer Drugs Product
Table 103. AVEO Pharmaceuticals Recent Developments/Updates
Table 104. Bionomics Corporation Information
Table 105. Bionomics Description and Business Overview
Table 106. Bionomics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 107. Bionomics Kidney Cancer Drugs Product
Table 108. Bionomics Recent Developments/Updates
Table 109. Bristol-Myers Squibb Corporation Information
Table 110. Bristol-Myers Squibb Description and Business Overview
Table 111. Bristol-Myers Squibb Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 112. Bristol-Myers Squibb Kidney Cancer Drugs Product
Table 113. Bristol-Myers Squibb Recent Developments/Updates
Table 114. Cerulean Pharma Corporation Information
Table 115. Cerulean Pharma Description and Business Overview
Table 116. Cerulean Pharma Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 117. Cerulean Pharma Kidney Cancer Drugs Product
Table 118. Cerulean Pharma Recent Developments/Updates
Table 119. Exelixis Corporation Information
Table 120. Exelixis Description and Business Overview
Table 121. Exelixis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 122. Exelixis Kidney Cancer Drugs Product
Table 123. Exelixis Recent Developments/Updates
Table 124. Genentech Corporation Information
Table 125. Genentech Description and Business Overview
Table 126. Genentech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 127. Genentech Kidney Cancer Drugs Product
Table 128. Genentech Recent Developments/Updates
Table 129. immatics biotechnologies Corporation Information
Table 130. immatics biotechnologies Description and Business Overview
Table 131. immatics biotechnologies Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 132. immatics biotechnologies Kidney Cancer Drugs Product
Table 133. immatics biotechnologies Recent Developments/Updates
Table 134. Immunicum Corporation Information
Table 135. Immunicum Description and Business Overview
Table 136. Immunicum Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 137. Immunicum Kidney Cancer Drugs Product
Table 138. Immunicum Recent Developments/Updates
Table 139. Ono Pharmaceutical Corporation Information
Table 140. Ono Pharmaceutical Description and Business Overview
Table 141. Ono Pharmaceutical Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 142. Ono Pharmaceutical Kidney Cancer Drugs Product
Table 143. Ono Pharmaceutical Recent Developments/Updates
Table 144. Onyx Therapeutics Corporation Information
Table 145. Onyx Therapeutics Description and Business Overview
Table 146. Onyx Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 147. Onyx Therapeutics Kidney Cancer Drugs Product
Table 148. Onyx Therapeutics Recent Developments/Updates
Table 149. Oxford BioMedica Corporation Information
Table 150. Oxford BioMedica Description and Business Overview
Table 151. Oxford BioMedica Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 152. Oxford BioMedica Kidney Cancer Drugs Product
Table 153. Oxford BioMedica Recent Developments/Updates
Table 154. Prometheus Laboratories Corporation Information
Table 155. Prometheus Laboratories Description and Business Overview
Table 156. Prometheus Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 157. Prometheus Laboratories Kidney Cancer Drugs Product
Table 158. Prometheus Laboratories Recent Developments/Updates
Table 159. Seattle Genetics Corporation Information
Table 160. Seattle Genetics Description and Business Overview
Table 161. Seattle Genetics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 162. Seattle Genetics Kidney Cancer Drugs Product
Table 163. Seattle Genetics Recent Developments/Updates
Table 164. Taiwan Liposome Corporation Information
Table 165. Taiwan Liposome Description and Business Overview
Table 166. Taiwan Liposome Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 167. Taiwan Liposome Kidney Cancer Drugs Product
Table 168. Taiwan Liposome Recent Developments/Updates
Table 169. Tracon Pharmaceuticals Corporation Information
Table 170. Tracon Pharmaceuticals Description and Business Overview
Table 171. Tracon Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 172. Tracon Pharmaceuticals Kidney Cancer Drugs Product
Table 173. Tracon Pharmaceuticals Recent Developments/Updates
Table 174. Wilex Corporation Information
Table 175. Wilex Description and Business Overview
Table 176. Wilex Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 177. Wilex Kidney Cancer Drugs Product
Table 178. Wilex Recent Developments/Updates
Table 179. Production Base and Market Concentration Rate of Raw Material
Table 180. Key Suppliers of Raw Materials
Table 181. Kidney Cancer Drugs Distributors List
Table 182. Kidney Cancer Drugs Customers List
Table 183. Kidney Cancer Drugs Market Trends
Table 184. Kidney Cancer Drugs Market Drivers
Table 185. Kidney Cancer Drugs Market Challenges
Table 186. Kidney Cancer Drugs Market Restraints
Table 187. Global Kidney Cancer Drugs Sales Forecast by Type (2023-2028) & (K Units)
Table 188. Global Kidney Cancer Drugs Sales Market Share Forecast by Type (2023-2028)
Table 189. Global Kidney Cancer Drugs Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 190. Global Kidney Cancer Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 191. Global Kidney Cancer Drugs Sales Forecast by Application (2023-2028) & (K Units)
Table 192. Global Kidney Cancer Drugs Sales Market Share Forecast by Application (2023-2028)
Table 193. Global Kidney Cancer Drugs Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 194. Global Kidney Cancer Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 195. Global Kidney Cancer Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 196. Global Kidney Cancer Drugs Sales Market Share Forecast by Region (2023-2028)
Table 197. Global Kidney Cancer Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 198. Global Kidney Cancer Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 199. Research Programs/Design for This Report
Table 200. Key Data Information from Secondary Sources
Table 201. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Kidney Cancer Drugs
Figure 2. Global Kidney Cancer Drugs Market Share by Type in 2021 & 2028
Figure 3. Angiogenesis Inhibitors Product Picture
Figure 4. mTOR Inhibitors Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Cytokine Immunotherapy (IL-2) Product Picture
Figure 7. Global Kidney Cancer Drugs Market Share by Application in 2021 & 2028
Figure 8. Renal Cell Carcinoma (RCC)
Figure 9. Transitional Cell Carcinoma (TCC)
Figure 10. Global Kidney Cancer Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Kidney Cancer Drugs Market Size (2017-2028) & (US$ Million)
Figure 12. Global Kidney Cancer Drugs Sales (2017-2028) & (K Units)
Figure 13. Kidney Cancer Drugs Sales Share by Manufacturers in 2021
Figure 14. Global Kidney Cancer Drugs Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Kidney Cancer Drugs Players: Market Share by Revenue in 2021
Figure 16. Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Kidney Cancer Drugs Sales Market Share by R

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global 5-Fluorouracil Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76

The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......

Global Carboplatin Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......

Global Neutropenia Drugs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96

The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......

Global Small Molecule Cancer Drug Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......

Global Capecitabine Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80

Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......

Global Oxaliplatin Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104

Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......

Global Cancer Treatment Drugs Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158

According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......

Global Capecitabine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93

According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......

Global Methotrexate Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95

According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs